| __timestamp | BioCryst Pharmaceuticals, Inc. | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 4326000 |
| Thursday, January 1, 2015 | 13047000 | 226206000 |
| Friday, January 1, 2016 | 11253000 | 94391000 |
| Sunday, January 1, 2017 | 13933000 | 53821000 |
| Monday, January 1, 2018 | 29514000 | 35463000 |
| Tuesday, January 1, 2019 | 37121000 | 46456000 |
| Wednesday, January 1, 2020 | 67929000 | 71318000 |
| Friday, January 1, 2021 | 118818000 | 135256000 |
| Saturday, January 1, 2022 | 159371000 | 102708000 |
| Sunday, January 1, 2023 | 213894000 | 129620000 |
In pursuit of knowledge
In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: ImmunityBio, Inc. and BioCryst Pharmaceuticals, Inc., from 2014 to 2023.
Over this period, BioCryst Pharmaceuticals saw a staggering 2,768% increase in SG&A expenses, peaking in 2023. ImmunityBio, on the other hand, experienced a more modest 2,894% rise, with a notable spike in 2015. By 2023, BioCryst's expenses were approximately 65% higher than ImmunityBio's, highlighting a significant divergence in their financial strategies.
These trends reflect the companies' strategic investments in marketing, administration, and sales, crucial for their growth and competitive positioning. Investors should consider these financial dynamics when evaluating potential opportunities in the biotech sector.
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing argenx SE and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.